In parallel, the KEYNOTE-158 study, centered on cervical cancer treatment, revealed that patients with advanced cervical cancer with prevalent PD-L1 expression had an overall response rate of 12.2% after pembrolizumab treatment (58). This evidence concerns the gene CD274 and cervical carcinoma.